Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule oligopeptide, classified as an experimental drug. It has not been approved for use in any country and is not currently in clinical trials beyond preclinical or early research phases. The structure features a biphenyl group linked via an amino and mercapto (thiol) pentanoyl chain to a butyric acid methyl ester moiety. There is no publicly available information on its mechanism of action, specific biological targets, or therapeutic indications. No developer or manufacturer has been identified for this compound[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-(2-{2-[(biphenyl-4-ylmethyl)-amino]-3-mercapto-pentanoylamino}-acetylamino)-3-methyl-butyric acid methyl ester.